These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20480739)

  • 21. [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
    Nielsen DL; Andersson M
    Ugeskr Laeger; 2007 Sep; 169(37):3085-7. PubMed ID: 17877954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Kümler I; Palshof JA; Andersson M
    Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 24. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
    Ahmed S; Sami A; Xiang J
    Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA; Stein S
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ErbB/HER receptor family in breast cancer--the more we search the more we learn.
    Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
    Ann Oncol; 2008 May; 19(5):1020-1. PubMed ID: 18356136
    [No Abstract]   [Full Text] [Related]  

  • 28. Updates on therapeutic approaches in HER2-positive disease.
    Dickler MN
    Clin Adv Hematol Oncol; 2010 Feb; 8(2):105-7. PubMed ID: 20386531
    [No Abstract]   [Full Text] [Related]  

  • 29. Trastuzumab and breast cancer: developments and current status.
    Tokunaga E; Oki E; Nishida K; Koga T; Egashira A; Morita M; Kakeji Y; Maehara Y
    Int J Clin Oncol; 2006 Jun; 11(3):199-208. PubMed ID: 16850126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lessons from breast cancer trials of HER2-kinase inhibitors.
    Krop IE
    Lancet Oncol; 2016 Mar; 17(3):267-268. PubMed ID: 26822399
    [No Abstract]   [Full Text] [Related]  

  • 31. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation.
    Campone M; Juin P; André F; Bachelot T
    Crit Rev Oncol Hematol; 2011 Jun; 78(3):195-205. PubMed ID: 20684884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.
    Spector N
    Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S94-9. PubMed ID: 18777948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Her-2 targeted therapy: beyond breast cancer and trastuzumab.
    Flaherty KT; Brose MS
    Curr Oncol Rep; 2006 Mar; 8(2):90-5. PubMed ID: 16507217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Novel target therapies used in breast cancer management].
    Semiglazova TIu; Semiglazov VV; Filatova LV; Gershanovich ML; Chudenko VA; Latipova DKh; Luk'ianchikova VS; Dashian GA; Paltuev RM
    Vopr Onkol; 2011; 57(5):592-600. PubMed ID: 22238928
    [No Abstract]   [Full Text] [Related]  

  • 36. Duration of trastuzumab for HER2-positive breast cancer.
    Montemurro F; Aglietta M
    Lancet Oncol; 2013 Jul; 14(8):678-9. PubMed ID: 23764182
    [No Abstract]   [Full Text] [Related]  

  • 37. Target therapy in elderly breast cancer patients.
    Carli P; Turchet E; Quitadamo D; Spada A; Miolo G; Lamaj E; Spazzapan S; Di Lauro V; Dolcetti R; Veronesi A; Crivellari D
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):422-31. PubMed ID: 22257652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managing trastuzumab-resistant breast cancer.
    Krop I
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):108-10. PubMed ID: 19367251
    [No Abstract]   [Full Text] [Related]  

  • 39. [Lapatinib treatment-option in trastuzumab-resistant breast cancer].
    Pikó B
    Magy Onkol; 2009 Dec; 53(4):369-75. PubMed ID: 20071309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?
    Ohno S; Tanaka K; Koga C; Nishimura S; Yamaguchi H; Kawaguchi H; Yoshiyama T; Nakamura Y
    Breast Cancer; 2012 Jul; 19(3):212-7. PubMed ID: 21630056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.